Compare NXGL & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXGL | MBIO |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 5.1M |
| IPO Year | N/A | 2023 |
| Metric | NXGL | MBIO |
|---|---|---|
| Price | $0.57 | $0.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 105.0K | 57.6K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.77 | N/A |
| Revenue Next Year | $46.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.53 |
| 52 Week High | $2.89 | $7.00 |
| Indicator | NXGL | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 61.11 |
| Support Level | $0.48 | $0.69 |
| Resistance Level | $0.64 | $0.80 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 43.31 | 87.70 |
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.